Publication Name	World Journal of Gastroenterology
Manuscript ID	112312
Country	Russia

Received	2025-07-23 02:03
Peer-Review Started	2025-07-23 02:04
To Make the First Decision
Return for Revision	2025-08-25 07:52
Revised	2025-08-25 14:05
Second Decision	2025-09-30 02:46
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-09-30 06:31
Articles in Press	2025-09-30 06:31
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-10-21 01:46
Publish the Manuscript Online	2025-10-27 08:08

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Breaking barriers in the first-line Helicobacter pylori treatment: Chinese multicenter trial validates vonoprazan-based triple therapy
Manuscript Source	Invited Manuscript
All Author List	Vasily Isakov and Alexei Goncharov
Funding Agency and Grant Number	Funding Agency Grant Number Ministry of Science and Higher Education of the Russian Federation FGMF-2025-0003
Corresponding Author	Vasily Isakov, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Federal Research Center of Nutrition, Biotechnology and Food Safety, 21 Kashirskoe Shosse, Moscow 115446, Russia. vasily.isakov@gmail.com
Key Words	Helicobacter pylori; First-line treatment; Vonoprazan; Triple therapy; Proton pump inhibitors
Core Tip	This editorial highlights a pivotal multicenter randomized controlled trial from China demonstrating that vonoprazan (VPZ)-based triple therapy achieves superior or non-inferior Helicobacter pylori eradication rates compared to standard bismuth quadruple regimens, even in high clarithromycin resistance regions. The 10-day VPZ-amoxicillin-clarithromycin regimen exceeded 90% per-protocol efficacy with fewer adverse events, offering a simplified, well-tolerated alternative aligned with global treatment goals. These findings underscore a shift in empirical first-line therapy and support the integration of VPZ into updated regional and international guidelines.
Publish Date	2025-10-27 08:08
Citation	<p>Isakov V, Goncharov A. Breaking barriers in the first-line Helicobacter pylori treatment: Chinese multicenter trial validates vonoprazan-based triple therapy. <i>World J Gastroenterol</i> 2025; 31(40): 112312</p>
URL	https://www.wjgnet.com/1007-9327/full/v31/i40/112312.htm
DOI	https://dx.doi.org/10.3748/wjg.v31.i40.112312

Full Article (PDF)	WJG-31-112312-with-cover.pdf
Manuscript File	112312_Auto_Edited_015531.docx
Answering Reviewers	112312-answering-reviewers.pdf
Audio Core Tip	112312-audio.m4a
Conflict-of-Interest Disclosure Form	112312-conflict-of-interest-statement.pdf
Copyright License Agreement	112312-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	112312-non-native-speakers.pdf
Peer-review Report	112312-peer-reviews.pdf
Scientific Misconduct Check	112312-scientific-misconduct-check.png
Scientific Editor Work List	112312-scientific-editor-work-list.pdf
CrossCheck Report	112312-crosscheck-report.pdf